In 2023, Zhifei Biotech will not forget its original intention, actively practice the mission of "preventing and curing diseases, and protecting human health", and has delivered satisfactory answers in various fields such as R&D, production, quality, and sales.
The company's operating performance continued to grow, and the operating income in the first three quarters was 3927.2 billion yuan, a year-on-year increase of 4115%, and a new breakthrough is expected in full-year results. While realizing its own development, the company has also made a positive contribution to the development of social economy, paying taxes of 59 in the first three quarters of 20237.8 billion yuan, up to now, the cumulative tax has exceeded 22 billion yuan, and the Zhifei system (including shareholding companies) has achieved the employment of nearly 9,000 people.
Today, the top ten news of Zhifei Biotech in 2023 are announced, let us review these exciting moments together, continue to forge ahead towards the goal of a world-class biopharmaceutical company in the new year, escort people's health with practical actions, and contribute more to the construction of a healthy China!
1. Zhifei Biotech renewed its contract with Merck"100 billion big order".
On January 21, Zhifei Biotech and Merck renewed the ** Distribution and Co-promotion Agreement, mainly on the basis of the previous agreement, the basic purchase amount of Merck and Co-Sharp & Dohme's five vaccine products that have obtained marketing authorization in Chinese mainland will be renewed.
During the validity period of the agreement, Zhifei will continue to purchase HPV vaccine, pentavalent rotavirus vaccine and other agreed products from Merck & Co., Ltd. in accordance with the agreement, with a total basic purchase amount of more than 100 billion yuan to effectively meet the vaccination needs of more people.
2. Vice Chairman of Zhifei BiotechnologyVice President Jiang Lingfeng attended the 14th National People's Congress
On March 5, the first session of the 14th National People's Congress opened at the Great Hall of the People in Beijing. Jiang Lingfeng, deputy to the National People's Congress, vice chairman and vice president of Zhifei Biotech, attended the 14th National People's Congress.
At this meeting, Jiang Lingfeng pointed to the current late start of the domestic biomedical upstream chain industry, and the core technology and key raw and auxiliary materials have been monopolized by foreign countries for a long time, focusing on the localization of raw and auxiliary materials in the biomedical industry, and hoped that the relevant departments will introduce relevant policies to encourage the substitution of localized materials, further simplify the relevant registration procedures, and formulate flexible and feasible evaluation systems and standards to provide technical support for the research on the substitution of domestic materials.
3. Zhifei Biotech was approved to set up a postdoctoral research workstation in Chongqing
On May 11, the Chongqing Municipal Human Resources and Social Security Bureau issued the "Notice on the Establishment of Municipal Postdoctoral Research Workstations in 6 Units including Chongqing Institute of Financial Technology" (Yuren Sheban 2023 No. 106), and Zhifei Biotech was successfully approved to set up a municipal postdoctoral research workstation, which can carry out the recruitment and training of postdoctoral talents.
The approval of the establishment of a postdoctoral research workstation marks a new step in the cultivation of high-level talents and the construction of an innovative scientific research platform for the company, and lays a solid foundation for the introduction and training of high-level research talents in the future. Zhifei will take this opportunity to accelerate the construction of high-level talent team, continuously improve the training mechanism of innovative talents, promote the deep integration of industry, university and research, and enhance the company's scientific and technological research and development and achievement transformation capabilities.
4. Zhifei Biotech Innovative Product Incubation Center was completed and put into use
On June 30, Zhifei Biotech Innovative Product Incubation Center was put into use, which will focus on the cutting-edge technology of the vaccine industry, carry out original technological innovation, overcome technical problems in the industry, and provide underlying technical support for the research and development of more innovative products.
With a construction area of more than 7,000 square meters, Zhifei Biotech Innovative Product Incubation Center plans to build a nucleic acid vaccine R&D technology platform, a new antigen screening and synthesis technology platform, a new adjuvant R&D technology platform, a vaccine delivery system technology platform, and a structure and quality technology platform, including recombinant proteins, recombinant adenovirus vectors, OMV, mRNA and other innovative vaccine technologies, at the same time, cultivate innovative talents, incubate new products, aim at the forefront of innovation, stimulate innovation vitality, gather more advantageous innovation projects, and create an innovation ecological chain.
5. Zhifei Luzhu won the first place in the top 100 small and medium-sized private enterprises in Beijing
On September 21, the Beijing Federation of Industry and Commerce and the people of Fengtai District jointly held the "2023 Beijing Top 100 Private Enterprises Conference". At the meeting, the "1+4" list of the top 100 private enterprises in Beijing was released, and Beijing Zhifei Luzhu, a wholly-owned subsidiary of Zhifei Biotech, was selected as one of the top 100 small and medium-sized private enterprises in Beijing, ranking firstIt was selected as one of the top 100 scientific and technological innovation private enterprises in Beijing, ranking 40th.
6. Zhifei Biologywith GSKReached a strategic cooperation
On October 8, Zhifei Biotech and GlaxoSmithKline (GSK Biotech, GSK Hong Kong, hereinafter collectively referred to as "GSK") signed the "Exclusive Distribution and Joint Promotion Agreement", under which the two parties carried out in-depth cooperation on the recombinant herpes zoster vaccine developed and produced by GSK, and reached a preliminary cooperation intention on the RSV vaccine developed and produced by GSK.
The signing of this agreement marks the official opening of the cooperation between the two parties. In the future, the two sides will work together to promote innovative and high-quality vaccine products to benefit more Chinese people and create better social and corporate benefits.
7. The theme interview activity of the "High-quality Development Research Tour" of the Propaganda Department of the CPC Central Committee entered Chongqing Zhirui Biomedical Industrial Park
On October 11, the "High-quality Development Research Trip" theme interview activity organized by the Propaganda Department of the CPC Central Committee entered Chongqing Zhirui Biomedical Industrial Park, one of the three major research and production bases of Zhifei Biotechnology. Nearly 50 reporters from central media and municipal media such as People's Daily, Xinhua News Agency, Radio and Television Group, Guangming, China News Service, Chongqing, Chongqing Radio and Television Group, etc., conducted on-the-spot investigations of Zhirui Biomedical Industrial Park to explore the secret of the high-quality development of Zhifei Biotechnology.
8. Zhifei BiologyIt has reached in-depth cooperation with Sun Yat-sen University and Sun Yat-sen University Cancer Center on the research and development of EBV vaccine
On October 27, Zhifei Biotech held a signing ceremony with Sun Yat-sen University and Sun Yat-sen University Cancer Center for the joint R&D and achievement transformation project of EBV vaccine, and the three parties officially signed the "Technology Transfer Contract" to further reach an in-depth cooperative relationship on the research and development of a number of EBV vaccine candidates. The three parties will actively promote the process of EBV vaccine from R&D to industrialization, and provide more strategies and options to protect people's lives and health.
9. Zhifei Biotech reached an agreement of intent with relevant parties on the acquisition of Chen'an Biotech, and further expanded its business territory
On the evening of November 23, the company announced that it intends to acquire 100% of the shares of Chongqing Chen'an Biopharmaceutical in cash, inject Chen'an Bio into the listed company, and further improve the company's layout of "preventing and curing diseases", so that the business territory of the listed company will be extended to cover the field of metabolic diseases such as diabetes and obesity, and at the same time, it will also enter the field of first-class biopharmaceuticals.
In the future, Zhifei Biotech will continue to empower the development of innovation through diversified models such as independent research and development, in vitro incubation, and cooperative introduction, so that good drugs can truly benefit the people, and strive to become a world-class biopharmaceutical company with "excellent products, outstanding brands, leading innovation, and modern governance".
10. Zhifei Biotech continued to fulfill its social responsibilities and won the "China Charity Award" and "People's Corporate Social Responsibility Award".
On May 29, the launching and donation ceremony of the ** Autonomous Region Tuberculosis Public Welfare Project was held in Lhasa. Anhui Zhifeilong Kema, a wholly-owned subsidiary of Zhifei Biotech, donated more than 10 million yuan to the project to help the tuberculosis prevention and control work of the ** autonomous region.
On August 15, Zhifei donated 10 million yuan to the flood-stricken areas of Hebei Province through the Chongqing Charity Federation to purchase ambulances, ECG machines and other materials urgently needed by local primary medical and health institutions to support local emergency medical services and post-disaster reconstruction.
On December 21, Zhifei donated 10 million yuan to the disaster areas of Gansu and Qinghai through the Chongqing Charity Federation, which was used for emergency rescue, people's livelihood assistance and post-disaster reconstruction in the affected areas.
Over the years, Zhifei has always adhered to the corporate tenet of "social benefits first, corporate benefits second", and while adhering to its own high-quality development, it has continued to focus on medical and health care, scholarships and student assistance, rural revitalization, disaster relief and other fields, and actively carried out charitable and public welfare activities, with a total donation of more than 400 million yuan.
In 2023, Zhifei Biotech won the 12th "China Charity Award" organized by the Ministry of Civil Affairs, and won the 18th "People's Corporate Social Responsibility Award - Enterprise of the Year Award" under the guidance of People's ** Society and sponsored by People's Daily Online.